Clinical Trials Browser

Gliosarcoma × cemiplimab × 90 days × Clear all

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 1 Not yet recruiting

Glioblastoma, Gliosarcoma